Efficacy of artificial liver support system in severe immune-associated hepatitis caused by camrelizumab: A case report and review of the literature

doi:10.12998/wjcc.v9.i17.4415

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 9, Issue 17

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (5208)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-3) series, Tables (1-1) series.

Item

Count

PDF

338

WORD

165

HTML

2848

Figures (1-3)

320

Tables (1-1)

254

Sum=3925

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

430

Download

853

Sum=1283

Jun 16, 2021 (publication date) through Nov 29, 2024

Times Cited of This Article

Times Cited (7)

Journal Information of This Article

Publication Name

World Journal of Clinical Cases

ISSN

2307-8960

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Case Report

World J Clin Cases. Jun 16, 2021; 9(17): 4415-4422
Published online Jun 16, 2021. doi: 10.12998/wjcc.v9.i17.4415

Full Size Figure Download Figure

Figure 1 Flow chart of liver function change and treatment intervention. LB: Liver biopsy; MP: Methylprednisolone; DPMAS: Dual plasma molecular adsorption system; PE: Plasma exchange; TBIL: Total bilirubin; ALP: Alkaline phosphatase; ALT: Alanine aminotransferase; UDCA: Ursodeoxycholic acid; INR: International normalized ratio.

Citation: Tan YW, Chen L, Zhou XB. Efficacy of artificial liver support system in severe immune-associated hepatitis caused by camrelizumab: A case report and review of the literature. World J Clin Cases 2021; 9(17): 4415-4422
URL: https://www.wjgnet.com/2307-8960/full/v9/i17/4415.htm
DOI: https://dx.doi.org/10.12998/wjcc.v9.i17.4415